Inadequate And Counterproductive: Industry Criticizes Turkey’s Local Drug Production Policy
Executive Summary
The general secretary of Turkey’s Association of Research based Pharmaceutical Companies (AIFD), Umit Dereli, tells the Pink Sheet why he thinks the government’s policy on local medicines production is wrong in terms of its scope, goal, and method.
You may also be interested in...
Turkish Decree Places New Caps On Drug Price Increases
In order to help curb the drugs bill, the Turkish Social Security Institution has decided to restrict the level of price increases that can be made on pharmaceutical products when the prices of those products are increased in reference or non-reference countries.
Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.
A Bright Moment At Last In Turkish Medtech Debt Payments Saga
Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.